Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00525083 · ClinicalTrials.gov registry record
Protein and Phospholipid Analysis of HDL in Patients With Very High Serum Levels of HDL-C
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- 19
- Enrollment target
NCT00525083: Clinical Trial study, sponsored by Vanderbilt University Medical Center.
NCT00525083 is a clinical trial that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00525083 was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- 19 participants
- Enrollment target
Study Summary
Coronary heart disease (CHD) is the single leading cause of death in the United States . Serum Cholesterol is known to have a direct impact on a number of human diseases through a variety of mechanisms. This is particularly true of cardiovascular disease. Measurement and manipulation of serum cholesterol has become a primary focus of primary care physicians and cardiologists when attempting to reduce risk of heart disease.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2005-06 |
| Est. Completion | 2014-11-03 |
Why NCT00525083 stopped before completion
NCT00525083 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00525083 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00525083 about?
NCT00525083 is a clinical study titled "Protein and Phospholipid Analysis of HDL in Patients With Very High Serum Levels of HDL-C". Coronary heart disease (CHD) is the single leading cause of death in the United States . Serum Cholesterol is known to have a direct impact on a number of human diseases through a variety of mechanisms. This is particularly true of cardiovascular disease. Measurement and manipulation of serum choles...
What is the current status of trial NCT00525083?
This trial is currently terminated. The enrollment target is 19 participants. The study started on 2005-06. Estimated completion is 2014-11-03.
Who is sponsoring clinical trial NCT00525083?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia